Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study

AIDS

Volumn 28, Issue 18, 2014, Pages 2649-2657

  Li, Jonathan Z ^a   Heisey, Andrea ^a   Ahmed, Hayat ^a   Wang, Hongying ^b   Zheng, Lu ^b   Carrington, Mary ^c,d   Wrin, Terri ^e   Schooley, Robert T ^f   Lederman, Michael M ^g   Kuritzkes, Daniel R ^a   Mellors, John ^h   Bedison, Annie ^h   Hu, Zixin ^h   Giguel, Francoise ^h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d HARVARD UNIVERSITY   (United States)

^e MONOGRAM BIOSCIENCES   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h Division of Infectious Diseases Brigham and Women's Hospital ^*  (United States)

Author keywords

Analytic treatment interruption; HIV; Reservoir; Therapeutic vaccine

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; HLA B27 ANTIGEN; HLA B57 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; CYTOKINE; VIRUS DNA; VIRUS RNA;

ALLELE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE STATUS; LATENT PERIOD; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; RETROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; VACCINATION; VIRUS LOAD; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; GENETICS; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MONONUCLEAR CELL; VIREMIA; VIROLOGY;

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; PLACEBOS; RETROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84925445545     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000478     Document Type: Article

References (37)

1. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487:482-485.
2. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8R T cells. Blood 2006; 107:4781-4789.
3. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551- 1557.
4. Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: Association with Gagspecific CD8 T cell responses. J Immunol 2009; 182:7828- 7837.
5. Graf EH, Pace MJ, Peterson BA, Lynch LJ, Chukwulebe SB, Mexas AM, et al. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance. PLoS One 2013; 8:e71879.
6. Garcia F, Leon A, Gatell JM, Plana M, Gallart T. Therapeutic vaccines against HIV infection. Hum Vaccin Immunother 2012; 8:569-581.
7. Macatangay BJ, Lawani MB, Riddler S, Wheeler ND, Bedison MA, Rinaldo CR, Mellors J. Dendritic cell-based HIV therapeutic vaccine increases residual viremia in individuals on ART [Abstract 143]. Conference on Retroviruses and Opportunistic Infections; 3-6 March 2014; Boston, MA.
8. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, Kuritzkes DR, et al. AIDS clinical trials group 5197: A placebocontrolled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010; 202:705- 716.
9. Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson MN, et al. Factors associated with viral rebound in HIV-1- infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis 2011; 203:976-983.
10. Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc 2008; 3:1240-1248.
11. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531- 4536.
12. Tobery TW, Dubey SA, Anderson K, Freed DC, Cox KS, Lin J, et al. A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects. AIDS Res Hum Retroviruses 2006; 22:1081-1090.
13. Trigona WL, Clair JH, Persaud N, Punt K, Bachinsky M, Sadasivan-Nair U, et al. Intracellular staining for HIV-specific IFN-gamma production: Statistical analyses establish reproducibility and criteria for distinguishing positive responses. J Interferon Cytokine Res 2003; 23:369-377.
14. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149.
15. Casazza JP, Bowman KA, Adzaku S, Smith EC, Enama ME, Bailer RT, et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis 2013; 207:1829-1840.
16. Persaud D, Luzuriaga K, Ziemniak C, Muresan P, Greenough T, Fenton T, et al. Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4R T-cell latent HIV reservoir. AIDS 2011; 25:2227-2234.
17. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix ML, et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: The ANRS Genome Wide Association 01 study. PLoS One 2008; 3:e3907.
18. Descours B, Avettand-Fenoel V, Blanc C, Samri A, Melard A, Supervie V, et al. Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin Infect Dis 2012; 54:1495-1503.
19. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001; 344:1668-1675.
20. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622.
21. McLinden RJ, Paris RM, Polonis VR, Close NC, Su Z, Shikuma CM, et al. Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). AIDS 2010; 26:1-9.
22. Montefiori DC, Hill TS, Vo HT, Walker BD, Rosenberg ES. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 2001; 75:10200-10207.
23. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 2001; 98:13288-13293.
24. Schweighardt B, Wrin T, Meiklejohn DA, Spotts G, Petropoulos CJ, Nixon DF, Hecht FM. Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption. J Acquir Immune Defic Syndr 2010; 53:36-46.
25. Salgado M, Rabi SA, O'Connell KA, Buckheit RW 3rd, Bailey JR, Chaudhry AA, et al. Prolonged control of replication-competent dual- Tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology 2011; 8:97.
26. Van Gulck E, Bracke L, Heyndrickx L, Coppens S, Atkinson D, Merlin C, et al. Immune and viral correlates of 'secondary viral control' after treatment interruption in chronically HIV-1 infected patients. PLoS One 2012; 7:e37792.
27. Nicastri E, Dori L, Buonomini AR, Tommasi C, De Nardo P, Bellagamba R, et al. HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy. AIDS 2012; 26:1451-1452.
28. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
29. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A 1999; 96:10958- 10961.
30. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 105:3879-3884.
31. Henrich TJ, Gallien S, Li JZ, Pereyra F, Kuritzkes DR. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J Virol Methods 2012; 186:68- 72.
32. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013; 9:e1003174.
33. Yerly S, Gunthard HF, Fagard C, Joos B, Perneger TV, Hirschel B, Perrin L. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 2004; 18:1951-1953.
34. Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis 2003; 188:1426-1432.
35. Ho Y, Shan L, Wang J, Hosmane N, Blankson JN, Siliciano RF. Characterization of noninduced HIV-1 proviruses dampens the hope for HIV-1 eradication [abstract 43]. 20th Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Atlanta, GA.
36. Sobolewski M, Cillo A, Lalama CM, Bosch RJ, Mellors J. A rapid virion recovery assay reveals a larger population of inducible proviruses in resting CD4R T cells than previously recognized [abstract 174LB]. 20th Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Atlanta, GA.
37. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4R T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol 2005; 304:3-15.